Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

RUOXINLIN AND OTHER DRUGS INCLUDED ON CHINA'S 2024 NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the "**Board**") of Luye Pharma Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announces that several of its innovative products (including new indications) have been included in the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2024 Version) (the "**2024 NRDL**"). These products include Ruoxinlin (toludesvenlafaxine hydrochloride extended-release tablets) which has made the list for the first time; Baituowei (goserelin microspheres for injection) which is included with a new indication for breast cancer; and Lipusu (paclitaxel liposome for injection) which is included in the regular catalogue of the list. The 2024 NRDL will officially take effect on January 1, 2025.

The Company believes that the inclusion of these products in the 2024 NRDL will not only significantly enhance patients' access to medication and reduce their financial burden, but also accelerate the commercialization of these products and further increase the returns for innovation.

ABOUT RUOXINLIN

Ruoxinlin (toludesvenlafaxine hydrochloride extended-release tablets) is a Class 1 innovative chemical drug for the treatment of Major Depressive Disorder ("**MDD**"). The drug has debuted on the NRDL for the first time following successful negotiations. It is China's first locally developed proprietary antidepressant approved for marketing through the pathway for Class 1 chemical drugs, marking a breakthrough in this therapeutic area as a "Made-in-China" innovative drug.

Nonclinical studies have showed that Ruoxinlin acts as a serotonin (5-HT)-norepinephrine (NE)-dopamine (DA) reuptake inhibitor (SNDRI). In addition, a PET/CT study has showed that Ruoxinlin can bind to DA transporters in the brains of both rats and healthy subjects, another piece of strong evidence proving it is an SNDRI. Clinical studies have demonstrated that it is able to treat MDD in a comprehensive and stable manner. Specifically, it significantly reduces anxiety, retardation/fatigue and anhedonia, improves cognitive abilities, and promotes the recovery of social functions. Additionally, it is safe and well-tolerated, without causing somnolence or negatively affecting sexual functioning, bodyweight, and lipid metabolism. A meta-analysis that reveals Ruoxinlin's superior efficacy than other 21 antidepressants has been published in the *Chinese Medical Journal*.

By effectively addressing the unmet needs of MDD patients, Ruoxinlin has become one of the fastest-growing new antidepressants in recent years. To date, more than 25,000 patients have benefited from the drug.

ABOUT BAITUOWEI

Baituowei (goserelin microspheres for injection) is the world's only marketed formulation of long-acting goserelin microspheres. It is indicated for treating prostate cancer in patients requiring androgen deprivation therapy (ADT), and treating breast cancer in premenopausal and perimenopausal women that can be treated with hormones. The drug was already included in the 2023 NDRL for its indication to treat prostate cancer. The 2024 NDRL expands its coverage to include the indication for treating breast cancer.

Baituowei was developed on the Group's globally leading microsphere platform. With its upgraded microsphere formulation and improved injection method, the product is able to balance efficacy, safety, and patient experience, providing a more convenient new option for patients. The Group and BeiGene are working together to commercialize this product in China.

ABOUT LIPUSU

Lipusu (paclitaxel liposome for injection) has been included in the regular catalogue of the 2024 NRDL, covering all of its indications, including non-small-cell lung cancer, ovarian cancer, and breast cancer.

Lipusu is the only marketed paclitaxel liposome for injection in the world. Its unique formulation allows it to target tumors and lymph nodes and have a longer half-life, making the drug more potent in killing tumor cells, and also safer and better-tolerated. Since its launch, the drug has been widely recognized by physicians and patients in clinical practice, and has also been recommended by multiple authoritative guidelines and consensuses for its efficacy and safety.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 28 November 2024

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Dr. LYU Dong; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.